Vor Biopharma Inc complete an upsized $176.9 million IPO, offering 9.83 million shares at $18 each.
The stock opened at $42.02 was jumped 104.9% in early action.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.56 |
|---|---|
| 52-week range | $0.49 - $1.87 |
| 50-day moving average | $0.83 |
| 200-day moving average | $0.94 |
| Wall St. target price | $10.14 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.70 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.661 from 2025-05-02
| 1 week (2025-04-29) | -2.79% |
|---|---|
| 1 month (2025-04-07) | 21.51% |
| 3 months (2025-02-07) | -53.12% |
| 6 months (2024-11-07) | -20.74% |
| 1 year (2024-05-07) | -62.44% |
|---|---|
| 2 years (2023-05-05) | -83.18% |
| 3 years (2022-05-06) | 5.07 |
| 5 years (2020-05-03) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -44.42% |
| Return on equity TTM | -94.52% |
| Profit margin | 0% |
| Book value | $0.78 |
| Market Capitalization | $82.5 million |
TTM: trailing 12 months
We're not expecting Vor Biopharma Inc to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Vor Biopharma Inc's shares have ranged in value from as little as $0.49 up to $1.87. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vor Biopharma Inc's is -0.212. This would suggest that Vor Biopharma Inc's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Vor Biopharma Inc has bucked the trend.
To put Vor Biopharma Inc's beta into context you can compare it against those of similar companies.
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .